Raising early capital means choosing a legal instrument, and that choice has consequences that tend to show up much later than the signing date. In this issue, we cover the three instruments founders encounter most often: SAFEs, convertible notes, and priced rounds.
Each creates a distinct legal relationship from the moment it’s signed both between the company and its investors, and between early investors and those who come after. This post covers what each one is in plain terms, before the mechanics. The next three issues will go deeper into each instrument.
SAFEs (Simple Agreement for Future Equity)
A SAFE is not equity and it is not a loan. It gives the investor a contractual right to receive equity at some point in the future, specifically, when the company closes a priced funding round. The investor hands over capital today; the company hands over nothing but a promise of shares, on terms defined at signing, once a qualifying event occurs.
SAFEs carry no interest and have no maturity date. They sit on the balance sheet as a kind of deferred obligation, invisible on the cap table until they convert. This makes them fast and low-friction: a SAFE can be signed in a day, with minimal legal cost on either side.
Convertible Notes
A convertible note is debt. The company borrows money from an investor with the expectation that the loan will not be repaid in cash, but will instead convert into equity at a future financing event. Like a SAFE, the actual share price is deferred; unlike a SAFE, the investor is legally a creditor in the meantime.
That distinction matters in practice. Convertible notes accrue interest over time, and they carry a maturity date – a deadline by which a qualifying financing must occur, or the debt technically falls due. In most cases investors extend or negotiate rather than demand repayment, but the approaching maturity date gives the investor real leverage if the company has not yet closed a round.
Convertible notes are common in jurisdictions where SAFEs have uncertain legal or tax treatment, with investors whose structure requires them to hold debt rather than pre-equity instruments, and in deals that involve enough complexity (representations, covenants, specific conditions) to warrant a proper debt contract rather than a simpler agreement.
Priced Rounds
A priced round is a full equity transaction. Investors buy newly issued shares at an agreed price per share, the company establishes a binding valuation, and the deal is documented with a complete set of investment agreements. There is no deferral: on closing, the investors are shareholders.
Priced rounds take longer to negotiate and document than SAFEs or notes, involve more legal costs and more extensive documents.
Priced rounds are more common at Series A and beyond, once a company has enough operating history to justify a formal valuation. That said, they are also used at seed stage for larger institutional rounds where investors want the legal protections and governance rights that come with holding actual shares from day one.
Instrument Comparison
The table below summarizes the key dimensions across the three instruments. It is a reference point for asking the right questions – not a recommendation.
| Dimension | SAFE | Convertible Note | Priced Round |
| Legal character | Future equity right (contract) | Debt instrument | Equity (shares issued now) |
| Interest | None | Yes | N/A |
| Maturity date | None | Yes (12–24 months typical) | N/A (closes on signing) |
| Valuation set at signing | No (cap only) | No (cap only) | Yes — binding |
| Voting rights | None until conversion | None until conversion | Yes (preferred share terms) |
| Governance | Minimal | Limited | Full (board, consent rights, pro-rata) |
| Typical use | Pre-seed / seed | Seed; bridge; non- US jurisdictions | Series A+; larger seed rounds |
| Complexity | Low | Medium | High |
Coming Up in This Series
The three instruments introduced here each deserve a closer look. In the next posts of this series, we will go deeper into each one individually: how the economics work, the more relevant terms, and what questions founders should be asking before they sign.
